Stanford, CA, United States
Stanford, CA, United States

Time filter

Source Type

"NCCN Foundation is proud to support this important resource which indeed will empower patients with thyroid cancer and their caregivers to make informed choices about their care," said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. "We are incredibly grateful for the generous support from our sponsors, ThyCa and Rockin' for the Cure, as their sponsorship for these resources gives patients access to the same treatment information that their doctors use." "Thyroid Cancer is challenging because it affects people of all ages from young children through seniors, is especially life-disrupting and stressful when diagnosed in younger patients, and needs lifelong monitoring and management even in low-risk patients," said Gary Bloom, ThyCa Executive Director, and Thyroid Cancer survivor of 21 years. "ThyCa is very pleased to support these important guidelines, which will be helpful resources for both patients and their caregivers." NCCN Guidelines for Patients are easy-to-understand adaptations based on the same clinical practice guidelines used by health care professionals around the world to determine the best way to treat a person with cancer. Each resource features unbiased expert guidance from the nation's leading cancer centers designed to help people living with cancer understand and discuss their treatment options with their providers. NCCN Guidelines for Patients and NCCN Quick Guide™ sheets—one-page summaries of key points in the patient guidelines—are written in plain language and include patient-friendly tools, such as questions to ask your doctor, a glossary of terms, and medical illustrations of anatomy, tests, and treatment.  NCCN Guidelines for Patients and NCCN Quick Guide™ sheets DO NOT replace the expertise and clinical judgment of the clinician. NCCN currently offers NCCN Guidelines for Patients for the following: Brain, Breast, Colon Distress, Esophageal, Kidney, Non-Small Cell Lung, Ovarian, Pancreatic, Prostate, Stomach, and Thyroid Cancers; Acute Lymphoblastic Leukemia; Adolescents and Young Adults with Cancer; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Hodgkin Lymphoma; Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Nausea and Vomiting; Non-Hodgkin's Lymphomas; Soft Tissue Sarcoma; and Waldenström's Macroglobulinemia. The NCCN Guidelines for Patients and NCCN Quick Guide™ sheet for Thyroid Cancer are available to download for free at NCCN.org/patients and on the NCCN Patient Guides for Cancer mobile app. NCCN Foundation® was founded by the National Comprehensive Cancer Network® (NCCN®) to empower people with cancer and advance oncology innovation. NCCN Foundation supports people with cancer and their caregivers at every step of their treatment journey by delivering unbiased expert guidance from the world's leading cancer experts through the library of NCCN Guidelines for Patients® and other patient education resources. NCCN Foundation is also committed to advancing cancer treatment by funding the nation's promising young investigators at the forefront of cancer research, initiating momentum in their careers and furthering the betterment of patients through their groundbreaking innovations. For more information about NCCN Foundation, visit NCCNFoundation.org. ThyCa: Thyroid Cancer Survivors' Association, Inc., an international nonprofit organization founded in 1995 and advised by thyroid cancer specialists, educates and supports patients and families through its website, online and face-to-face support groups, one-to-one support, over 50 videos with experts on its YouTube Channel, handbooks on all thyroid cancer types, downloadable low-iodine cookbook, online newsletter, and materials in 10 languages. ThyCa sponsors seminars, workshops, and the annual International Thyroid Cancer Survivors' Conference, as well as Thyroid Cancer Awareness Month, year-round awareness programs for early detection, and thyroid cancer research funds and research grants. For more information visit http://www.thyca.org. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT. [1] Robert I. Haddad, MD, et. al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma, Version 1.2017. © 2017 National Comprehensive Cancer Network, Inc.  Available at NCCN.org. Accessed: May 8, 2017 [2] "Cancer Stat Facts: Thyroid Cancer." Surveillance, Epidemiology, and End Results Program. National Cancer Institute, n.d. Web. 08 May 2017. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nccn-publishes-new-patient-education-resources-for-thyroid-cancer----one-of-the-most-commonly-diagnosed-cancers-in-women-in-the-united-states-300456776.html


The study, "Are We on the Same Page? Patient and Provider Perceptions about Exercise in Cancer Care: A Focus Group Study," published in the May 2017 issue of JNCCN – Journal of the National Comprehensive Cancer Network is available free of charge on JNCCN.org until July 30, 2017. "Our results indicate that exercise is perceived as important to patients with cancer, both from a patient and physician perspective; however, physicians are reluctant to consistently include PA recommendations in their patient discussions. Our findings highlight the value of examining both patient and provider attitudes and behavioral intentions," said Dr. Smaradottir. "While we uncovered barriers to exercise recommendations, questions remain on how to bridge the gap between patient and provider preferences." Where they exercise is important to patients. More than 80% of those surveyed noted that they would prefer a home-based exercise regimen that could be performed in alignment with their personal schedules and symptoms. Patients also noted a preference that exercise recommendations come from their oncologists, as they have an established relationship and feel that their oncologists best understand the complexities of their personalized treatment plans. Although patients prefer PA at home, Dr. Smaradottir found that practitioners wish to refer patients to specialist care for exercise recommendations. The practitioners surveyed noted not only mounting clinic schedules, but also a lack of education about appropriate PA recommendations for patients. Furthermore, they expressed concern about asking patients to be more physically active during chemotherapy and radiation, and also expressed trepidation about prescribing PA to frail patients with limited mobility. "We were surprised by the gap in expectations regarding exercise recommendation between patients and providers. Many providers, ourselves included, thought patients would prefer to be referred to an exercise center, but they clearly preferred to have a home based program recommended by their oncologist," Dr. Smaradottir said. Exercise was felt to be an equally important part of treatment and well-being for patients with early stage cancer treated with curative intent as well as patients receiving palliative therapy. For the focus groups, the investigators interviewed 20 patients aged 45 and older – 10 with stage I-III non-metastatic cancer after adjuvant therapy and 10 with stage IV metastatic disease undergoing palliative treatment, both across multiple tumor types. Additionally, the researchers interviewed nine practitioners.  The authors note that while the sample size is limited, because the subjects of the study all hailed from the same institution, the study provides an understanding of how the group as a whole has the potential to influence the practice of PA recommendations. Smaradottir et al note that physician education is paramount and suggest that successful implementation of an education protocol should begin with a multidisciplinary collaboration between treating providers and physical therapy specialists, exercise physiologists, and other sub specialties. They add that the emphasis of such a program should be on a patient-centered approach, making the recommendations specific for each patient. "Indeed, physicians, fellows, and residents who collaborate with a PA specialist through a shared-care clinic visit will gain valuable education about how to discuss exercise recommendations with their patients," said Dr. Smaradottir. Currently, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship recommend exercise for cancer survivors. "Physical activity is emerging as an important adjunct therapy in the treatment of multiple cancers, and there is consensus that physical activity is helpful to patients with cancer and survivors in terms of augmenting symptom burden and maintaining overall health. This study highlights the discord between what we think is important and what we do in actual practice as providers. It also highlights patients' desire to remain physically active and to receive guidance from their oncologists regarding what they can and should be doing. Based on the results of this and other studies, further work on both defining what the optimal physical activity recommendation for patients should be and determining how best to train our oncologic workforce to implement recommendations is needed," said Crystal Denlinger, MD, Chief of Gastrointestinal Medical Oncology and Associate Professor, Department of Hematology/Oncology at Fox Chase Cancer Center, and Chair of the NCCN Guidelines® Panel for Survivorship. Free access to this article is available until July 30, 2017, on JNCCN.org. About JNCCN – Journal of the National Comprehensive Cancer Network More than 24,000 oncologists and other cancer care professionals across the United States read JNCCN–Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about best clinical practices, health services research, and translational medicine. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside Press. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit http://www.nccn.org/jnccn/subscribe.asp JNCCN 360 is a new online resource for oncology professionals featuring up-to-date news, literature, trials, clinical perspectives on current therapies, and much more. Visit JNCCN360.org About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/despite-evidence-that-it-benefits-patients-with-cancer-study-finds-most-oncologists-dont-discuss-exercise-with-patients-300456186.html


The Request for Proposals (RFP) issued by NCCN and Pfizer strongly encourages proposals that address the use of clinical pathways in community centers, low-resource centers, and centers that focus on the treatment of underserved patients with cancer. All U.S.-based organizations, including NCCN Member Institutions, community affiliates of NCCN Member Institutions and other academic medical centers, and community cancer centers are encouraged to submit proposals. "NCCN recognizes the emerging role of evidence-based clinical care pathways in cancer, and we are pleased to once again align with Pfizer IGLC to improve the quality of care of people with breast cancer, particularly those in underserved communities across the United States," said Susan Most, RN, MBA Director, Clinical Operations, NCCN ORP. The RFP seeks proposals in two specific areas of interest: The NCCN ORP, organized to obtain funding to support scientifically meritorious research studies at NCCN Member Institutions and other centers, leads the organization for review and evaluation of applications. A review committee, led by NCCN and including a medical representative from Pfizer, will decide which proposals will receive funding. Grant funding will be provided by Pfizer IGLC. The RFP deadline is June 26, 2017. For more information about NCCN ORP and view the RFP, visit NCCN.org/ORP. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nccn-and-pfizer-address-quality-improvement-in-breast-cancer-through-clinical-pathways-300460672.html

Loading Stanford Cancer Institute collaborators
Loading Stanford Cancer Institute collaborators